Success Metrics

Clinical Success Rate
96.4%

Based on 54 completed trials

Completion Rate
96%(54/56)
Active Trials
10(14%)
Results Posted
63%(34 trials)
Terminated
2(3%)

Phase Distribution

Ph phase_1
14
19%
Ph not_applicable
3
4%
Ph phase_2
13
18%
Ph phase_4
15
21%
Ph phase_3
22
30%

Phase Distribution

14

Early Stage

13

Mid Stage

37

Late Stage

Phase Distribution67 total trials
Phase 1Safety & dosage
14(20.9%)
Phase 2Efficacy & side effects
13(19.4%)
Phase 3Large-scale testing
22(32.8%)
Phase 4Post-market surveillance
15(22.4%)
N/ANon-phased studies
3(4.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

96.4%

54 of 56 finished

Non-Completion Rate

3.6%

2 ended early

Currently Active

10

trials recruiting

Total Trials

73

all time

Status Distribution
Active(12)
Completed(54)
Terminated(2)
Other(5)

Detailed Status

Completed54
Active, not recruiting8
unknown4
Recruiting2
Terminated2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
73
Active
10
Success Rate
96.4%
Most Advanced
Phase 4

Trials by Phase

Phase 114 (20.9%)
Phase 213 (19.4%)
Phase 322 (32.8%)
Phase 415 (22.4%)
N/A3 (4.5%)

Trials by Status

not_yet_recruiting11%
suspended11%
unknown45%
enrolling_by_invitation11%
recruiting23%
terminated23%
completed5474%
active_not_recruiting811%

Recent Activity

Clinical Trials (73)

Showing 20 of 73 trialsScroll for more
NCT07537088Phase 4

Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease

Not Yet Recruiting
NCT06739122Phase 3

A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

Recruiting
NCT07313813Phase 1

A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus

Active Not Recruiting
NCT05478707Phase 2

Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

Suspended
NCT06851962Phase 4

Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.

Active Not Recruiting
NCT07417618

INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)

Active Not Recruiting
NCT07417631

Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.

Active Not Recruiting
NCT07319286Phase 1

Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus

Enrolling By Invitation
NCT07282041Phase 2

Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis

Recruiting
NCT06779929

Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

Active Not Recruiting
NCT07088718

Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data

Completed
NCT07096063

Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk

Completed
NCT06257966Phase 3

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

Active Not Recruiting
NCT04255433Phase 3

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

Completed
NCT06235086Phase 3

A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus

Active Not Recruiting
NCT05564039Phase 4

A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

Completed
NCT06901648Phase 2

A Study of HS-20094 in Patients With T2DM

Completed
NCT05680129Phase 3

A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM

Completed
NCT05659537Phase 4

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India

Completed
NCT04862234Phase 4

Perioperative Stress Hyperglycemia in General and Vascular Surgery Patients

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
73